Smithkline Beecham Corporation

Glaxo Wellcome Inc.

Glaxo Inc.

Glaxosmithkline LLC

David Harold Drewry

Peter J Brown

Michael Luzzio

Brian Edward Marron

Paul Bamborough

Scott Howard Dickerson

David Drysdale Miller

Robert Carl Andrews

Michael John Alberti

Andrew B McElroy

Timothy Francis Gallagher

Rodolfo Cadilla

Neil W Johnson

Dennis Lee

David Kendall Jung

Jeffrey Michael Axten

Domingos J Silva

Marc W Andersen

Jiri Kasparec

Deborah Lynne Bryan

Krista B Goodman

David John Cowan

Frank Navas, Iii

David Norman Deaton

Jason Daniel Speake

Brian Evans

Michael Joseph Bishop

Robert Neil Hunter, Iii

Michael Gregson

Brad Richard Henke

Robert A Stavenger

Michael Howard Rabinowitz

Michael David Gaul

Stephen J Hodson

Peter L Myers

Thomas H Faitg

Jeffrey M Ralph

Stewart Alwyn Noble

Darren Victor Steven Green

Howard G Davies

Michael A Foley

James M Salovich

Sjoerd Nocolaas Wadman

Frank J Schoenen

Eric Cleveland Bigham

Deanna Trojan Garrison

James Andrew Linn

The present invention relates to a compound represented by the following formula: or a pharmaceutically acceptable salt thereof;

Anthranilamide inhibitors of aurora kinase

The present invention relates to aminopyrazine derivatives, compositions and medicaments containing the same, as well as processes for the preparation and use of such compounds, compositions and medicaments. Such aminopyrazine derivatives are useful in the treatment of diseases associated with inappropriate tyrosine and/or serine/threonine kinase activity.

Aminopyrazine derivatives and compositions

The present invention relates to indazolo-tetrahydropyrimidine-carboxamide derivatives, compositions and medicaments containing the same, as well as processes for the preparation and use of such compounds, compositions and medicaments. Such indazolo-tetrahydropyrimidine-carboxamide derivatives are useful in the treatment of diseases associated with inappropriate ROCK-1 kinase.

Indazolo-tetrahydropyrimidine-carboxamide derivative kinase inhibitors

The present invention relates to aminopyrazine derivatives, compositions and medicaments containing the same, as well as processes for the preparation and use of such compounds, compositions and medcicaments. Such aminopyrazine derivatives are useful in the treatment of diseases associated with inappropriate tyrosine and/or serine/threonine kinase activity.

Benzimidazolyl-pyridine derivatives, which are useful as SGK-1 inhibitors are described herein. The described invention also includes methods of making such benzimidazolyl-pyridine derivatives as well as methods of using the same in the treatment of diseases mediated by inappropriate SGK-1 activity.

Chemical compounds

Aminopyridine derivatives of the following formula I which exhibit pharmacological activity at estrogen receptors alpha (ER&#x3b1;) and beta (ER&#x3b2;) are described herein. The described invention also includes compositions and medicaments containing the aminopyridine derivatives as well as processes for the preparation and use of such compounds, compositions and medicaments.

Aminopyridine derivatives as estrogen receptor modulators

Compound of formula (I) or a pharmaceutically acceptable salt or solvate thereof are disclosed. Such compounds are useful in the treatment of Alpha-1A mediated diseases or conditions such as urinary incontinence.

Imidazoline derivatives as alpha-1A adrenoceptor ligands

Oxindole derivatives, specifically pyrrolo&lsqb;3,2-f&rsqb;quinoline-2-ones, which are useful as CDK4 inhibitors are described herein. The described invention also includes methods of making such oxindole derivatives as well as methods of using the same in the treatment of hyperproliferative diseases.

Oxindole derivatives

A family of compounds having the general structural formula

Formamides as therapeutic agents

Oxazole derivatives as antagonists of alpha 1C andrenergic receptors

Aminobutanoic acids of the following formula (I): ##STR1## where R.sup.1 -R.sup.5 are a variety of substituents, novel intermediates, a pharmaceutical composition for treating inflammatory diseases, demyelinating diseases, and tumor metastasis, methods for such treatment and processes for preparing compounds of formula (I).

Aminobutanoic acid compounds having metalloprotease inhibiting properties

Compounds are described of the formula ##STR1## wherein: R.sup.1 is C.sub.3-6 alkyl or C.sub.1-3 alkylthioC.sub.1-3 alkyl;

Cyclic imide derivatives, compositions and use

Growing community of inventors

Durham, NC, United States of America

David Harold Drewry